We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mucosis Receives Financial Support from the Dutch Government
News

Mucosis Receives Financial Support from the Dutch Government

Mucosis Receives Financial Support from the Dutch Government
News

Mucosis Receives Financial Support from the Dutch Government

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mucosis Receives Financial Support from the Dutch Government"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mucosis B.V. has announced that it has received an innovation credit line of up to €5 million from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs.

Mucosis will use these funds to further advance the clinical development of its proprietary SynGEM® prefusion F RSV vaccine candidate through human proof-of-concept studies. These studies aim to demonstrate both safety and protection against a challenge with RSV in healthy volunteers.

"We are delighted to have the support of the Dutch government in such an important disease area. Combined with our recently announced strategic partnership with BCHT of China and new investment round, we have now raised over €10 million in the first half of 2014. Advancing the SynGEM® program to human clinical trials through these funds will create a substantial company value inflection point in the near term", said Thomas Johnston, CEO of Mucosis.

Johnston continued, "Additionally, we see this significant funding as a further validation of our clinical-stage Mimopath® platform and its potential to combat the most challenging of infectious diseases.”

Advertisement